Welcome to our dedicated page for CTS SEC filings (Ticker: CTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CTS Corporation filings document operating results, Regulation FD investor materials and governance disclosures for a manufacturer of sensors, actuators and electronic components. Form 8-K reports furnish quarterly and annual earnings releases, webcast slides and investor presentations tied to the company's end-market strategy and financial outlook.
CTS regulatory filings also cover proxy governance and compensation matters, board and executive officer changes, material agreements, and financing arrangements, including an unsecured revolving credit facility. These records describe the company's capital structure, leadership, treatment of furnished materials under the Exchange Act and risk language for forward-looking statements.
Pacioni Mark R. reported acquisition or exercise transactions in this Form 4 filing.
CTS Corp’s Chief Legal and Administrative Officer, Mark R. Pacioni, received a restricted stock award of 3,693 shares of common stock on February 11, 2026, valued at $57.15 per share. The grant was made under the CTS Corporation 2018 Equity and Incentive Compensation Plan.
The restricted shares vest in equal installments over three years, beginning on the first anniversary of the grant date, and are subject to his continued service. Following this award, Pacioni beneficially owns 8,293 shares of CTS common stock, held directly.
CTS Corporation Senior Vice President Pratik Trivedi received an equity grant of 3,500 shares of common stock. The Form 4 reports this as an acquisition at a reference price of $57.15 per share, increasing his directly held stake to 11,438 shares.
The award is restricted stock granted under the CTS Corporation 2018 Equity and Incentive Compensation Plan. It vests in equal installments over three years, beginning on the first anniversary of the grant date, and is contingent on continued service with the company.
Agrawal Ashish reported acquisition or exercise transactions in this Form 4 filing.
CTS Corporation reported that its CFO, Ashish Agrawal, received a grant of common stock under the CTS Corporation 2018 Equity and Incentive Compensation Plan.
The award covers 6,002 shares of restricted stock at $57.15 per share. These shares vest in equal installments over three years, starting on the first anniversary of the grant date, as long as he continues in service. After this grant, Agrawal directly owns 106,744 shares of CTS common stock.
A shareholder of CTS has filed a notice of proposed sale under Rule 144 for 13,522 shares of common stock, with an aggregate market value of $764,155.26. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 02/12/2026.
The filing notes that these shares were acquired through multiple restricted stock vesting events under a registered plan in exchange for services rendered. The notice also includes a representation that the seller is not aware of any undisclosed material adverse information about CTS’s current or prospective operations.
Wasatch Advisors filed an amended Schedule 13G reporting its beneficial ownership in CTS Corp. It reports holding 2,262,448 shares, representing 7.8% of the company’s common stock. Wasatch has sole voting power over 1,538,275 shares and sole dispositive power over all 2,262,448 shares.
The firm states the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of CTS Corp.
CTS Corp officer Pratik Trivedi filed an amended insider trading report to correct a prior tax-withholding entry tied to vesting of restricted stock. On February 5, 2026, 125 shares of common stock were disposed of at $54.19 per share to cover tax obligations.
After this correction, Trivedi directly beneficially owns 7,938 shares of CTS common stock. The amendment states that no other changes were made beyond updating the number of shares withheld for taxes.
CTS Corp President & CEO and director Kieran M. O'Sullivan reported two insider transactions on common stock dated February 9, 2026. He disposed of a total of 6,980 shares through tax-withholding dispositions tied to restricted stock vesting, valued at $55.58 per share. According to the filing, the shares were surrendered to satisfy tax withholding obligations when restricted stock awards vested. After these transactions, he directly owned 403,750 shares of CTS common stock.
Agrawal Ashish reported disposition transactions in a Form 4 filing for CTS. The filing lists transactions totaling 4,314 shares at a weighted average price of $55.58 per share. Following the reported transactions, holdings were 104,229 shares.
CTS Corporation furnished an investor presentation outlining recent performance, strategy, and 2026 guidance. For the twelve months ended December 2025, revenue was $541.3 million with adjusted EBITDA margin of 22.8% and adjusted diluted EPS of $2.23.
The business is increasingly diversified: industrial revenue was $140 million (up 12% year over year), medical revenue $85 million (up 21%), and aerospace & defense revenue $83 million (up 20%), while transportation revenue was $234 million (down 7%). Diversified end markets now represent 57% of revenue.
CTS reported free cash flow of $86.4 million in 2025 and has returned about $300 million to shareholders since 2013 through dividends and repurchases. For 2026, the company targets revenue of $550–$580 million and adjusted diluted EPS of $2.30–$2.45, supported by secular trends in automation, healthcare innovation, and electrification.
CTS Corporation reported stronger results for the fourth quarter and full year 2025, driven by growth in diversified industrial, medical, and aerospace & defense markets and better profitability. Fourth-quarter sales were $137.3 million, up 9% year over year, with diversified end markets up 16% and transportation down 1%. Net earnings rose to $19.7 million, and diluted EPS increased to $0.67 from $0.38, helped by higher gross and EBITDA margins.
For full-year 2025, sales reached $541.3 million, up 5%, while net earnings grew to $65.3 million and diluted EPS to $2.19 from $1.80. Diversified end markets grew 16% and represented 57% of revenue, partially offsetting a 7% decline in transportation revenue. Adjusted gross margin improved to 38.5% and adjusted EBITDA margin to 22.8%. Operating cash flow was $102.1 million and free cash flow $86.4 million, supporting $62 million returned to shareholders in 2025.
For 2026, CTS guides revenue of $550–$580 million and adjusted diluted EPS of $2.30–$2.45, assuming continued growth in diversified markets and softness in commercial-vehicle-related sales, with an expected tax rate of 21–23% excluding discrete items.